Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Lead-in study treatment assignment and final dose for patients who entered the extension study
| Lead-in study | Placebo | Levomilnacipran ER | ||
|---|---|---|---|---|
| 40 mg/day | 80 mg/day | 120 mg/day | ||
| Study 1 (assigned fixed-dose) | 107 | 97 | 83 | 89 |
| Study 2 (final flexible dose) | 125 | 29 | 23 | 46 |
| Study 3 (final flexible dose)a | 124 | 26 | 26 | 48 |
ER extended-release
aIn study 3, a final daily levomilnacipran ER dose of 20 or 160 mg was inadvertently taken by one patient each; these two patients were not included in the final dose count
